Fig. 3From: Would treatment decisions about secondary prevention of CVD based on estimated lifetime benefit rather than 10-year risk reduction be cost-effective?A histogram of the numbers of patients identified for treatment using the lifetime benefit-based strategy and the 10-year risk-based strategy stratified for age groups (< 55, 56–70, > 70)Back to article page